首页> 外文OA文献 >Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics.

【2h】

Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics.

机译：奥地利多发性骨髓瘤的第三线治疗的实际应用：奥地利骨髓瘤登记（amR）分析使用下一代骨髓瘤治疗前的治疗前景和临床结果。

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Ella Willenbacher; Roman Weger; Ursula Rochau; Uwe Siebert; Wolfgang Willenbacher;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Low Beclin-1 expression predicts improved overall survival in patients treated with immunomodulatory drugs for multiple myeloma and identifies autophagy inhibition as a promising potentially druggable new therapeutic target: an analysis from The Austrian Myeloma Registry (AMR) [J] . Willenbacher Wolfgang, Thangavadivel Shanmugapriya, Greil Richard, Leukemia and lymphoma . 2016,第10期

机译：低Beclin-1表达预测多发性骨髓瘤用免疫调节药物治疗的患者的总生存期提高，并将自噬抑制确定为有希望的潜在可药物治疗的新治疗靶标：奥地利骨髓瘤注册机构（AMR）的分析
2. Bone marrow microenvironmental CD4+and CD8+lymphocyte infiltration patterns define overall- and progression free survival in standard risk multiple myeloma - an analysis from the Austrian Myeloma Registry [J] . Willenbacher Wolfgang, Willenbacher Ella, Zelle-Rieser Claudia, Leukemia and lymphoma . 2016,第6期

机译：骨髓微环境CD4 +和CD8 +淋巴细胞浸润模式定义了标准风险多发性骨髓瘤的总体生存和无进展生存-奥地利骨髓瘤注册中心的一项分析
3. Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population-based study from the Danish national multiple myeloma registry [J] . Redder Louise, Klausen Tobias W., Vangsted Annette Juul, British Journal of Haematology . 2021,第1期

机译：验证英国骨髓瘤研究联盟风险概况，新诊断的多发性骨髓瘤患者患者的新临床预测模型，没有资格获得自体干细胞移植; 丹麦国家多骨髓瘤登记处的基于人口的研究
4. A Label-Free Proteomic Analysis of Low Abundance Multiple Myeloma Clinical Samples [C] . Ricky D. Edmondson, Veronica MacLeod, Sheeno Thyparambil, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2009

机译：无标记的蛋白质组学分析低丰度多骨髓瘤临床样本
5. Pre-Clinical Strategies to Overcome Drug-Resistant Multiple Myeloma: Predictive Transcriptomics and Targeting the Myeloma Epigenome [D] . Harding, Taylor Stiver. 2018

机译：克服毒性多发性骨髓瘤的前临床策略：预测转录组织和靶向骨髓瘤外形组织
6. Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics [O] . Ella Willenbacher, Roman Weger, Ursula Rochau, -1

机译：奥地利对多发性骨髓瘤的三线疗法的实际应用：在使用下一代骨髓瘤治疗剂之前奥地利骨髓瘤注册机构（AMR）对治疗前景和临床结果的分析
7. Clinical features and survival outcomes in patients with multiple myeloma: analysis of web-based data from the Korean Myeloma Registry. [O] . Kim SJ, Kim K, Kim BS, 2010

机译：多发性骨髓瘤患者的临床特征和生存结局：韩国骨髓瘤注册中心基于网络的数据分析。

Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics.

著录项

相似文献

相关主题

期刊订阅